The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Biosimilar Hormones Market Grow Between 2026 And 2030?
The biosimilar hormones market has experienced rapid expansion in its size over recent years. It is projected to increase from $6.22 billion in 2025 to $7.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.5%. The historical growth of this market was driven by factors such as the rising prevalence of diabetes and hormonal disorders, the significant cost of branded hormone therapies, an increasing aging population, growing awareness of hormone replacement therapies, and the expansion of hospital and retail pharmacy networks.
The biosimilar hormones market size is projected to undergo substantial expansion in the upcoming years, with an anticipated value of $18.12 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.9%. This projected growth throughout the forecast period can be largely attributed to the expiration of patents for significant biologic hormones, bolstered regulatory support for biosimilars, a burgeoning demand for affordable endocrine treatments, the proliferation of online pharmacy distribution channels, and increased investment in biosimilar research and development. Noteworthy trends expected in this timeframe include the increasing adoption of biosimilar hormones as economical alternatives, a rising need for insulin and growth hormone biosimilars, enhanced acceptance of biosimilar hormone therapies among medical professionals, the expanded application of biosimilars in chronic and lifestyle-related illnesses, and streamlined regulatory pathways supporting biosimilar approvals.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp
Which Strong Drivers Are Impacting The Biosimilar Hormones Market Growth?
The increasing financial outlay on healthcare is anticipated to drive the expansion of the biosimilar hormones market in the future. This outlay encompasses all funds expended by individuals, entities, or states for the prevention, treatment, and management of various health issues. The rise in healthcare spending stems from progress in medical technology, where novel diagnostic methods, therapeutic approaches, and innovative treatments frequently incur greater expenses, consequently boosting total health sector spending. An increase in healthcare costs stimulates the adoption of biosimilar hormones, driven by a greater need for economical treatments and broader patient accessibility throughout healthcare frameworks. For example, data from December 2024, provided by the US-based Centers for Medicare & Medicaid Services (the body managing Medicare and Medicaid), indicated that in 2023, U.S. health care expenditures grew by 7.5%, reaching $4.9 trillion, which equates to approximately $14,570 per person. Consequently, the expanding healthcare expenditure is fueling the growth of the biosimilar hormones market.
Which Segments Define The Biosimilar Hormones Market Segment Structure?
The biosimilar hormones market covered in this report is segmented –
1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types
2) By Application: Research & Biotechnology, Therapeutics, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics
Subsegments:
1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance
2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)
3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management
4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders
5) By Other Types: Thyroid Hormones, Corticosteroids
Which Trends Are Shaping Growth In The Biosimilar Hormones Market?
Major companies in the biosimilar hormones market are developing new products, such as the Sogroya (somapacitan-beco) injection, to boost their profitability. Sogroya (somapacitan-beco) is a prescribed analogue of human growth hormone (GH) used for individuals diagnosed with growth hormone deficiency (GHD). For instance, in April 2023, Novo Nordisk, a pharmaceutical company from Denmark, obtained FDA approval for a new indication for Sogroya (somapacitan-beco) injection for treating children aged 2.5 years and older who experience growth failure due to insufficient endogenous growth hormone secretion. Sogroya distinguishes itself as the sole once-weekly growth hormone (GH) therapy designed for both children and adults. This approval was based on results from the phase 3 REAL4 trial, which demonstrated Sogroya’s efficacy in addressing growth hormone deficiency (GHD) in pediatric patients.
Who Are The Established Players Within The Biosimilar Hormones Market?
Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy’s Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt
Get The Full Biosimilar Hormones Market Report:
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
Which Region Is The Top Contributor To The Biosimilar Hormones Market By Share?
North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Biosimilar Hormones Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
Browse Through More Reports Similar to the Global Biosimilar Hormones Market 2026, By The Business Research Company
Hormonal Contraceptives Market Report 2026
https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report
Biosimilar Growth Hormone Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report
Parathyroid Hormones Market Report 2026
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model